China’s Insurance Industry Moves to Standardize Drug Coverage: Draft Commercial A-List Now Open for Feedback
As NHSA pilots C-List reimbursement models, a parallel effort by the Insurance Association of China has produced its first national formulary draft—offering a framework that could define future specialty drug access under Huiminbao and beyond.
China’s Commercial Insurance Catalog Accelerates Expanding Beyond Category C Drug List
Led by the Insurance Association of China, this initiative alongside the NHSA-led Category C Drug List, is reshaping funding pathways, pricing strategies, and market access for innovative medicines.
NHSA Fast-Tracks China's First Category C Drug List to Expand Commercial Funding for Innovative Medicines
The launch of the Category C Drug List marks a major milestone in China’s reimbursement landscape for innovative therapies. Its success will hinge on transparent selection criteria, fair pricing strategies, and broad market adoption.
Pioneering Value-Based Care in China: A Conversation with Dr. Felix Lee, Co-CEO of The GBA Healthcare Group
This success story emphasizes the importance of aligning healthcare innovation with a nation's infrastructure and social security framework to ensure practical, scalable, and sustainable care delivery and payment models.
Advances in New Technology Add-On Payments for Innovative Medicine in China’s DRG/DIP Framework
In July, China’s National Healthcare Security Administration introduced the CHS-DRG Grouping Plan (Version 2.0), expanding the number of
Capitalizing on Specialized Medical Services in China: Opportunities for Innovative Life Sciences Manufacturers
To take advantage of these opportunities, manufacturers must focus on three key success factors.
Three Key Trends Shaping Pricing for Innovative Non-VBP Medical Devices in China
Understanding and strategically applying these trends is crucial for optimizing pricing strategies and enhancing market adoption of innovative medical technologies in China.
5 Trillion-Yuan Equipment Renewal and China's National Quota System for Large Medical Equipment
In China, large medical equipment is managed through a planned allocation and permit system. Medical institutions must follow specific plans, meet clinical and functional requirements, and have the necessary technical infrastructure and qualified staff.
